New Frontier Data 8.23.23New Frontier Data 8.23.23New Frontier Data 8.23.23New Frontier Data 8.23.23
  • Solutions
    • Market Segments
      • Retailers & Dispensaries Business Data Solutions: Because you Wouldn't Leave Home Without a Map. Consumer Research, Customer Acquisition, and Competitive Conquesting
      • InvestorsBusiness Intelligence Data: It's what's De-Risking Cannabis. Market Intelligence, Opportunity Modeling, Due-Diligence Validation, and Risk Mitigation
      • BrandsBecause "cool" is not a brand strategy. Find the white space, Determine the market, and Model the revenue
      • Agencies & Consultants Unleash the Power of Informed Campaigns! +160M Probable cannabis consumers, +60M Cannabis Retail Visitors, Custom Audience Builder, and Cannabis Specific Marketing Reporting
      • Academia regulatory understanding, retail business intelligence and Medical Patient Research
    • Problems Solved
      • Customer AcquisitionTarget, engage, and retain customers.
      • Market Intelligence & ForecastingMaximize your profits, minimize risks.
      • Custom Research & ReportsKnow your market, grow your business.
      • Brand Visibility & ExposureBoost your business with our sponsorships.
      • Analytics for the Medical Cannabis SectorData for healthcare, policies, and patient care.
  • Products
    • Equio Make Informed Decisions with actionable Insights
    • NXTeck Transform your approach to customer acquisition
    • Custom Research
    • Analyst Reports
    • SponsorshipsBoost your business with our market.
    • CMedAccess extensive medical patient data
  • Resources
    • Blog
    • Events & Webinars
    • Podcast
    • Newsletter - Sign-Up Cannabit
  • Company
    • About Us
    • Board & Advisors
    • Our Partners
    • In The News
    • Press Releases & Media Kit
  • Equio Login
✕

Brazil Patient Participation Levels

  • Home
  • Cannabis Insights
  • Brazil Patient Participation Levels
img 147
Can Constellation Brands’ Entry into the Market Lead to Banking Reform?
December 2, 2017
New Frontier Data thumbnail
2 Million Patients Impacted by Failure to Renew Rohrabacher-Blumenauer Amendment?
December 7, 2017
December 3, 2017
Categories
  • Cannabis Insights
  • Cannabit
Tags
img 176
  • An estimated 22.2 million Brazilians suffer from chronic pain in the lower back and neck.
  • Were Brazil to legalize medical cannabis, within the first 36 months of sales the number of qualified patients could reach 959,000 under a restrictive list of qualifying conditions (i.e., not including chronic pain), or roughly 3.4 million under an expansive list of conditions (covering chronic pain).
  • An expansive program featuring chronic pain as a qualifying condition and patient counts of 3.4 million patients would translate to annual revenues of roughly BRL 4.4 billion (USD 1.4 billion).
Share
FacebookTwitterLinkedInPinterest
0

Related posts

4 1 2025 Cannabit Alcohol use by cannabis consumers
April 1, 2025

Cannabis Infused Beverages: The New Frontier of Intoxicating Libations?


Read more
Gender and purchasing
March 18, 2025

Gender differences and cannabis purchasing behavior


Read more
3 4 2025 Cannabit Consumer Density
March 4, 2025

Prohibition does little to impact supply and demand


Read more

Comments are closed.

Brazil Patient Participation Levels

©2014-2025 New Frontier Data

HEADQUARTERS

5614 Connecticut Ave NW #331
Washington, DC 20015
info@nullnewfrontierdata.com
844-420-D8TA (3882)

MEDIA INQUIRIES

media@nullnewfrontierdata.com

FOLLOW US

social icon social icon social icon social icon social icon

COMPANY

FAQs
CONTACT US
CAREERS
PRESS RELEASES & MEDIA KIT
PRIVACY POLICY
TERMS OF USE